

Benjamin M Scirica

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5790638/publications.pdf>

Version: 2024-02-01

125
papers

10,261
citations

87723

38
h-index

33814

99
g-index

125
all docs

125
docs citations

125
times ranked

10860
citing authors

#	ARTICLE	IF	CITATIONS
1	Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2013, 369, 1317-1326.	13.9	3,017
2	Vorapaxar in the Secondary Prevention of Atherothrombotic Events. <i>New England Journal of Medicine</i> , 2012, 366, 1404-1413.	13.9	841
3	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2021, 384, 129-139.	13.9	662
4	Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non-ST-Elevation Acute Coronary Syndromes<SUBTITLE>The MERLIN-TIMI 36 Randomized Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1775.	3.8	448
5	Effect of Ranolazine, an Antianginal Agent With Novel Electrophysiological Properties, on the Incidence of Arrhythmias in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Circulation</i> , 2007, 116, 1647-1652.	1.6	422
6	Vorapaxar in Patients With Peripheral Artery Disease. <i>Circulation</i> , 2013, 127, 1522-1529.	1.6	261
7	Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 356-366.	5.5	224
8	Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2017, 40, 69-76.	4.3	205
9	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. <i>New England Journal of Medicine</i> , 2018, 379, 1107-1117.	13.9	205
10	Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. <i>Circulation</i> , 2019, 139, 1384-1395.	1.6	205
11	Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 ^Â P-TIMI 50 trial. <i>Lancet</i> , 2012, 380, 1317-1324.	6.3	202
12	The Verdict Is Still Out. <i>Circulation</i> , 2006, 113, 2128-2151.	1.6	167
13	Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 ^Â P)-TIMI 50 trial. <i>American Heart Journal</i> , 2009, 158, 335-341.e3.	1.2	166
14	Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease. <i>Circulation</i> , 2016, 133, 997-1005.	1.6	163
15	Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. <i>Circulation</i> , 2016, 134, 304-313.	1.6	143
16	Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	2.1	139
17	The potential role and rationale for treatment of heart failure with sodium-glucose cotransporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017, 19, 1390-1400.	2.9	139
18	The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and) Tj ETQq0 0 0 rgBf.4 Overloda10 Tf 50		

#	ARTICLE	IF	CITATIONS
19	Relationship Between Nonsustained Ventricular Tachycardia After Non-â€œST-Elevation Acute Coronary Syndrome and Sudden Cardiac Death. <i>Circulation</i> , 2010, 122, 455-462.	1.6	109
20	Surgical Ineligibility and Mortality Among Patients With Unprotected Left Main or Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2014, 130, 2295-2301.	1.6	109
21	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 140, 1569-1577.	1.6	94
22	Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 Trial. <i>European Heart Journal</i> , 2011, 32, 697-705.	1.0	77
23	Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2015, 38, 1145-1153.	4.3	73
24	Validation of the Thrombolysis In Myocardial Infarction (TIMI) risk score for unstable angina pectoris and non-â€œST-elevation myocardial infarction in the TIMI III registry. <i>American Journal of Cardiology</i> , 2002, 90, 303-305.	0.7	72
25	Clinical Application of C-Reactive Protein Across the Spectrum of Acute Coronary Syndromes. <i>Clinical Chemistry</i> , 2007, 53, 1800-1807.	1.5	72
26	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. <i>Lancet, The</i> , 2018, 392, 2269-2279.	6.3	70
27	Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-â€œST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. <i>American Heart Journal</i> , 2006, 151, 1186.e1-1186.e9.	1.2	63
28	Remote Optimization of Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2020, 5, 1430.	3.0	62
29	Response to Letter Regarding Article, â€œHeart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trialâ€. <i>Circulation</i> , 2015, 132, e121-2.	1.6	61
30	Quantitative EEG reactivity and machine learning for prognostication in hypoxic-ischemic brain injury. <i>Clinical Neurophysiology</i> , 2019, 130, 1908-1916.	0.7	58
31	Concentrations of C-Reactive Protein and B-Type Natriuretic Peptide 30 Days after Acute Coronary Syndromes Independently Predict Hospitalization for Heart Failure and Cardiovascular Death. <i>Clinical Chemistry</i> , 2009, 55, 265-273.	1.5	54
32	Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. <i>European Heart Journal</i> , 2010, 31, 1993-2005.	1.0	54
33	Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2015, 38, 2142-2150.	4.3	54
34	Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	53
35	Extracorporeal Membrane Oxygenation in Adults With Cardiogenic Shock. <i>Circulation</i> , 2015, 131, 676-680.	1.6	52
36	Ischemia Detected on Continuous Electrocardiography After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1411-1421.	1.2	50

#	ARTICLE	IF	CITATIONS
37	Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. <i>Europace</i> , 2015, 17, 32-37.	0.7	46
38	Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk. <i>European Heart Journal</i> , 2018, 39, 2255-2262.	1.0	45
39	Development of an entirely remote, non-physician led hypertension management program. <i>Clinical Cardiology</i> , 2019, 42, 285-291.	0.7	43
40	Digital Care Transformation. <i>Circulation</i> , 2021, 143, 507-509.	1.6	40
41	Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack. <i>Circulation</i> , 2015, 132, 1871-1879.	1.6	39
42	Long-Term Post-Discharge Risks in Older Survivors of Myocardial Infarction With and Without Out-of-Hospital Cardiac Arrest. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1981-1990.	1.2	39
43	Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. <i>Heart</i> , 2014, 100, 1762-1769.	1.2	38
44	Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. <i>American Journal of Medicine</i> , 2016, 129, 340.e1-340.e8.	0.6	34
45	Cardiac arrest and clinical characteristics, treatments and outcomes among patients hospitalized with ST-elevation myocardial infarction in contemporary practice: A report from the National Cardiovascular Data Registry. <i>American Heart Journal</i> , 2015, 169, 515-522.e1.	1.2	33
46	Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. <i>Circulation</i> , 2022, 146, 808-818.	1.6	33
47	Serum potassium levels, cardiac arrhythmias, and mortality following non-ST-elevation myocardial infarction or unstable angina: insights from MERLIN-TIMI 36. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 18-25.	0.4	32
48	Combination of Clinical Exam, MRI and EEG to Predict Outcome Following Cardiac Arrest and Targeted Temperature Management. <i>Neurocritical Care</i> , 2018, 29, 396-403.	1.2	32
49	Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. <i>Circulation</i> , 2019, 139, 366-375.	1.6	32
50	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. <i>Circulation</i> , 2021, 143, 470-478.	1.6	32
51	Use of Biomarkers in Predicting the Onset, Monitoring the Progression, and Risk Stratification for Patients with Type 2 Diabetes Mellitus. <i>Clinical Chemistry</i> , 2017, 63, 186-195.	1.5	31
52	Quantitative Electroencephalogram Trends Predict Recovery in Hypoxic-Ischemic Encephalopathy*. <i>Critical Care Medicine</i> , 2019, 47, 1416-1423.	0.4	26
53	Effect of Acridinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1693.	3.8	25
54	Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). <i>American Journal of Cardiology</i> , 2019, 123, 145-152.	0.7	25

#	ARTICLE	IF	CITATIONS
55	Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1095-1106.	1.2	25
56	Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN-TIMI 36 Trial. <i>Clinical Cardiology</i> , 2015, 38, 469-475.	0.7	24
57	Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2 ^o P-TIMI 50 trial. <i>Vascular Medicine</i> , 2020, 25, 124-132.	0.8	24
58	Treatment of Elevated Cholesterol. <i>Circulation</i> , 2005, 111, e360-3.	1.6	23
59	Effect of stimulus type and temperature on EEG reactivity in cardiac arrest. <i>Clinical Neurophysiology</i> , 2016, 127, 3412-3417.	0.7	23
60	Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. <i>Diabetes Research and Clinical Practice</i> , 2017, 130, 24-33.	1.1	22
61	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials. <i>Circulation</i> , 2021, 143, 685-695.	1.6	22
62	Continuous electrodermal activity as a potential novel neurophysiological biomarker of prognosis after cardiac arrest – A pilot study. <i>Resuscitation</i> , 2015, 93, 128-135.	1.3	21
63	Beatquency domain and machine learning improve prediction of cardiovascular death after acute coronary syndrome. <i>Scientific Reports</i> , 2016, 6, 34540.	1.6	20
64	MRI-EEG correlation for outcome prediction in postanoxic myoclonus. <i>Neurology</i> , 2020, 95, e335-e341.	1.5	20
65	Prognosis in the Thrombolysis in Myocardial Ischemia III Registry according to the Braunwald unstable angina pectoris classification. <i>American Journal of Cardiology</i> , 2002, 90, 821-826.	0.7	19
66	High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2 ^o P - TIMI 50 Trial. <i>Clinical Chemistry</i> , 2017, 63, 307-315.	1.5	19
67	Relation of T-Wave Alternans to Mortality and Nonsustained Ventricular Tachycardia in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome from the MERLIN-TIMI 36 Trial of Ranolazine Versus Placebo. <i>American Journal of Cardiology</i> , 2014, 114, 17-23.	0.7	18
68	Extraction of Ejection Fraction from Echocardiography Notes for Constructing a Cohort of Patients having Heart Failure with reduced Ejection Fraction (HFrEF). <i>Journal of Medical Systems</i> , 2018, 42, 209.	2.2	18
69	Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36. <i>Journal of the American Heart Association</i> , 2021, 10, e017401.	1.6	18
70	Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosis. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 1531-1540.	0.8	17
71	Rationale and design of a navigator-driven remote optimization of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction. <i>Clinical Cardiology</i> , 2020, 43, 4-13.	0.7	17
72	Impact of a Multidisciplinary Treatment Pathway for Atrial Fibrillation in the Emergency Department on Hospital Admissions and Length of Stay: Results of a Multi-Center Study. <i>Journal of the American Heart Association</i> , 2019, 8, e012656.	1.6	16

#	ARTICLE	IF	CITATIONS
73	Drug-induced thrombocytopenia and thrombosis: Evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 95-102.	1.0	15
74	Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patientsâ€“Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. <i>American Heart Journal</i> , 2018, 202, 39-48.	1.2	15
75	Ranolazine in patients with angina and coronary artery disease. <i>Current Cardiology Reports</i> , 2007, 9, 272-278.	1.3	14
76	The Association of Previous Revascularization With In-Hospital Outcomes in Acute Myocardial Infarction Patients. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1954-1962.	1.1	14
77	Outcomes in patients undergoing percutaneous ventricular assist device implantation for cardiogenic shock. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 108-116.	0.4	14
78	Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2Â°P)â€“TIMI 50. <i>Journal of the American Heart Association</i> , 2016, 5,	1.6	13
79	Delayed Deterioration of EEG Background Rhythm Post-cardiac Arrest. <i>Neurocritical Care</i> , 2017, 26, 411-419.	1.2	13
80	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. <i>Diabetes Care</i> , 2021, 44, 2573-2581.	4.3	13
81	Regional Distribution of Brain Injury After Cardiac Arrest. <i>Neurology</i> , 2022, 98, .	1.5	13
82	Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2016, 39, 1329-1337.	4.3	12
83	Workflow Automation for a Virtual Hypertension Management Program. <i>Applied Clinical Informatics</i> , 2021, 12, 1041-1048.	0.8	12
84	Racial and Ethnic Disparities in Postcardiac Arrest Targeted Temperature Management Outcomes*. <i>Critical Care Medicine</i> , 2020, 48, 56-63.	0.4	9
85	Valvular heart disease in pregnancy. <i>Current Cardiology Reports</i> , 2006, 8, 83-89.	1.3	8
86	Evaluation of glucose management during therapeutic hypothermia at a Tertiary Academic Medical Center. <i>Resuscitation</i> , 2015, 89, 64-69.	1.3	8
87	Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2Â°P-TIMI 50 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 164-172.	0.4	8
88	Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program. <i>American Heart Journal</i> , 2022, 243, 15-27.	1.2	8
89	A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study. <i>European Heart Journal</i> , 2007, 28, 2070-2076.	1.0	7
90	Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 353-360.	1.0	7

#	ARTICLE	IF	CITATIONS
91	Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2 ^Â P-TIMI 50. <i>Journal of the American Heart Association</i> , 2021, 10, e018673.	1.6	7
92	Long-Term Evaluation of the Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2018, 5, 5-15.	0.5	7
93	Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy. <i>European Heart Journal</i> , 2018, 39, 193-200.	1.0	6
94	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003006.	1.6	6
95	Evaluation of the Usage and Dosing of Guideline-Directed Medical Therapy for Heart Failure With Reduced Ejection Fraction Patients in Clinical Practice. <i>Journal of Pharmacy Practice</i> , 2021, , 089719002110048.	0.5	6
96	Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial). <i>PLoS ONE</i> , 2021, 16, e0259372.	1.1	6
97	Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA 2 ^Â P-TIMI 50). <i>American Journal of Cardiology</i> , 2016, 117, 1055-1058.	0.7	5
98	Implementation of an Emergency Department High-Sensitivity Troponin Chest Pain Pathway in the United States. <i>Critical Pathways in Cardiology</i> , 2019, 18, 1-4.	0.2	5
99	Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2 ^Â P-TIMI 50 Trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 190-199.	0.4	5
100	Phenotyping to Facilitate Accrual for a Cardiovascular Intervention. <i>Journal of Clinical Medicine Research</i> , 2019, 11, 458-463.	0.6	5
101	Magnetic Resonance Spectroscopy of Hypoxic-Ischemic Encephalopathy After Cardiac Arrest. <i>Neurology</i> , 2022, 98, .	1.5	5
102	Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Nonâ€STâ€Segment Elevation Myocardial Infarction Discharged Without Inâ€hospital Revascularization. <i>Journal of the American Heart Association</i> , 2016, 5, e002784.	1.6	4
103	Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet) Tj ETQq1 1 0.784314 rgBT /Overlo 1.2	1.2	4
104	Tirzepatide for diabetes: on track to SURPASS current therapy. <i>Nature Medicine</i> , 2022, 28, 450-451.	15.2	4
105	Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2 ^Â P-TIMI 50 trial. <i>Vascular Medicine</i> , 2019, 24, 159-161.	0.8	3
106	Extending i2b2 into a framework for semantic abstraction of EHR to facilitate rapid development and portability of Health IT applications. <i>AMIA Summits on Translational Science Proceedings</i> , 2019, 2019, 370-378.	0.4	3
107	â€The Doctor Is Outâ€: New Tactics and Soldiers for Our Losing Battle Against Hypertension. <i>Circulation</i> , 2022, 145, 1629-1631.	1.6	3
108	Response to Letter Regarding Article, â€Surgical Ineligibility and Mortality Among Patients With Unprotected Left Main or Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Interventionâ€. <i>Circulation</i> , 2015, 132, e156.	1.6	2

#	ARTICLE	IF	CITATIONS
109	Long-Term Management and Unmet Needs After an Acute Coronary Syndrome Event. American Journal of Cardiology, 2015, 115, 29A-35A.	0.7	2
110	In Search of the 1-Hour Rule-Out for Acute Myocardial Infarction. Clinical Chemistry, 2015, 61, 1427-1429.	1.5	2
111	High-Sensitivity Troponin in the Triage of Acute Decompensated Heart Failure. JACC: Heart Failure, 2016, 4, 600-602.	1.9	2
112	NT-proBNP: Can We Better Utilize Biomarkers in Patients With Diabetes?. Diabetes Care, 2020, 43, 2904-2905.	4.3	2
113	Practice pattern of use of high sensitivity troponin in the outpatient settings. Clinical Cardiology, 2020, 43, 1573-1578.	0.7	2
114	Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. American Journal of Cardiology, 2020, 125, 1577-1581.	0.7	2
115	Assessing the effect of publication of clinical guidelines on the management of unstable angina and non-ST elevation myocardial infarction in the TIMI III (1990-1993) and the GUARANTEE (1995-1996) Registries. Critical Pathways in Cardiology, 2002, 1, 150-8.	0.2	2
116	Reevaluation of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors. Clinical Cardiology, 0, , .	0.7	2
117	Hypertensive Heartbreak. New England Journal of Medicine, 2021, 384, 2145-2152.	13.9	1
118	Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers. Respiratory Research, 2021, 22, 272.	1.4	1
119	Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P/TIMI 50 Trial. Journal of the American Heart Association, 2021, 10, e021412.	1.6	1
120	Chronic angina: definition, prevalence, and implications for quality of life. Reviews in Cardiovascular Medicine, 2009, 10 Suppl 1, S3-10.	0.5	1
121	Appropriate invasive and conservative treatment approaches for patients with non-ST-elevation MI. Current Treatment Options in Cardiovascular Medicine, 2006, 8, 13-21.	0.4	0
122	Editorial commentary: Treating patients with diabetes and cardiovascular disease—Does the glucose matter?. Trends in Cardiovascular Medicine, 2016, 26, 180-181.	2.3	0
123	Microangiopathy, Arterial Stiffness, and Risk Stratification in Patients With Type 2 Diabetes—Reply. JAMA Cardiology, 2017, 2, 821.	3.0	0
124	The Impact of Exacerbation History on the Safety and Efficacy of Acclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial. International Journal of COPD, 2021, Volume 16, 689-699.	0.9	0
125	Efficacy of Acclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial. Advances in Therapy, 2021, 38, 5381-5397.	1.3	0